Chiasma, Inc.
ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS
Last updated:
Abstract:
This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM) and/or a 2.sup.nd somatostatin receptor ligand (SRL).
Status:
Application
Type:
Utility
Filling date:
7 May 2020
Issue date:
18 Mar 2021